Cumulative Fluid Balance during Extracorporeal Membrane Oxygenation and Mortality in Patients with Acute Respiratory Distress Syndrome

Li-Chung Chiu 1,2,3 *, Li-Pang Chuang 1, Shih-Wei Lin 1, Yu-Ching Chiou 4, Hsin-Hsien Li 5,6,7, Chung-Chi Huang 1,5,11, Shaw-Woei Leu 1,4 and Kuo-Chin Kao 1,5,11

Abstract: Extracorporeal membrane oxygenation (ECMO) is considered a salvage therapy in cases of severe acute respiratory distress syndrome (ARDS) with profound hypoxemia. However, the need for high-volume fluid resuscitation and blood transfusions after ECMO initiation introduces a risk of fluid overload. Positive fluid balance is associated with mortality in critically ill patients, and conservative fluid management for ARDS patients has been shown to shorten both the duration of mechanical ventilation and time spent in intensive care, albeit without a significant effect on survival. Nonetheless, few studies have addressed the influence of fluid balance on clinical outcomes in severe ARDS patients undergoing ECMO. In the current retrospective study, we examined the impact of cumulative fluid balance (CFB) on hospital mortality in 152 cases of severe ARDS treated using ECMO. Overall hospital mortality was 53.3%, and we observed a stepwise positive correlation between CFB and the risk of death. Cox regression models revealed that CFB during the first 3 days of ECMO was independently associated with higher hospital mortality (adjusted hazard ratio 1.110 [95% CI 1.027–1.201]; p = 0.009). Our findings indicate the benefits of a conservative treatment approach to avoid fluid overload during the early phase of ECMO when dealing with severe ARDS patients.

Keywords: acute respiratory distress syndrome; extracorporeal membrane oxygenation; cumulative fluid balance; mortality
1. Introduction

Extracorporeal membrane oxygenation (ECMO) is considered a rescue therapy for life-threatening hypoxemia in patients with severe acute respiratory distress syndrome (ARDS) [1–4]. Oxygen delivery during ECMO depends on the flow of blood through the circuit, which is limited primarily by the size of the drainage cannula, the diffusion properties of the membrane oxygenator and the concentration of hemoglobin. Increasing hemoglobin concentrations via red blood cell transfusion is commonly used to maintain adequate oxygen delivery during ECMO [1–6]. During the initial phase of ECMO, high-volume fluid resuscitation and blood transfusions are often required to ensure sufficient blood flow and to correct anemia or coagulopathy [1,6,7]. However, difficulties in maintaining normal extracellular fluid volumes can lead to fluid overload with corresponding effects on clinical outcomes [7].

Positive fluid balance is associated with a higher risk of death in cases of sepsis and critically ill patients [8–12]. In ARDS patients, optimal fluid management should provide adequate oxygen delivery to the body and avoid increases in lung edema, which could further impair gas exchange [13]. One randomized study reported that the use of a conservative fluid strategy in patients with ARDS could improve lung function and shorten the duration of mechanical ventilation and time spent in intensive care, albeit without a significant influence on 60-day mortality [14]. One systemic review and meta-analysis revealed that a conservative fluid strategy in cases of ARDS increased the number of ventilator-free days and decreased the length of stays in the intensive care unit (ICU) but without significant benefits pertaining to mortality [15].

ARDS patients who are not in shock should be treated using a conservative fluid strategy; however, fluid management in severe ARDS patients undergoing ECMO remains controversial with few published reports. Previous studies have reported that early positive fluid balance was independently associated with mortality in patients undergoing ECMO support [16,17]; however, none of those studies focused on the subgroup of patients with severe ARDS receiving ECMO. Our objective in the current study was to investigate the effect of cumulative fluid balance (CFB) during the early phase of ECMO on clinical outcomes and hospital mortality in patients with severe ARDS.

2. Materials and Methods

2.1. Study Design and Patients

This study focused on patients with severe ARDS who underwent ECMO between May 2006 and October 2015 in medical and surgical ICUs at a tertiary-care referral facility in Taiwan (Chang Gung Memorial Hospital (CGMH); 3700-bed general ward; 278-bed adult ICU). Exclusion criteria were as follows: (1) age < 20 years, (2) malignancies with poor prognosis within 5 years, (3) significant underlying comorbidities or severe multiple organ failure refractory to treatment, (4) end-stage renal disease, and (5) mortality within 3 days after ECMO initiation. At our facility, the decision to initiate ECMO cannulation is made by the treating intensivist in consultation with a cardiac surgeon, whereas the decision to initiate renal replacement therapy (RRT) is made by the treating intensivist in consultation with a nephrologist. During this study period, the criterion for ECMO initiation in severe ARDS patients was persistent hypoxemia (PaO$_2$/FiO$_2$ ratio <80 mmHg) for at least 6 h, despite aggressive mechanical ventilation support such as positive end-expiratory pressure (PEEP) >10 cm H$_2$O or peak inspiratory pressure >35 cm H$_2$O. All severe ARDS patients with ECMO support were deeply sedated and paralyzed with continuous neuromuscular blockade during the initial phase of ECMO support, and respiratory mechanics data were collected during neuromuscular blockade. Based on experience, the criteria for weaning from ECMO were resolving lung infiltration, lung compliance > 20 mL/cm H$_2$O, PaO$_2$ > 60 mmHg as well as PaCO$_2$ < 45 mmHg under FiO$_2$ ≤ 0.4, PEEP ≤ 6–8 cm H$_2$O, and peak inspiratory pressure ≤ 30 cm H$_2$O. The local Institutional Review Board for Human Research approved this study (CGMH IRB No. 201600632B0), and the need for informed consent was waived due to the retrospective nature of our analysis.
2.2. Definitions

ARDS was defined in accordance with the Berlin criteria [18]. Mechanical power was calculated using the following equation [19]:

\[
\text{Mechanical power (Joules/minutes)} = 0.098 \times \text{tidal volume} \times \text{respiratory rate} \times (\text{peak inspiratory pressure} - \frac{1}{2} \times \text{driving pressure}).
\]

Acute kidney injury was defined according to the KDIGO (Kidney Disease: Improving Global Outcomes) classification system and staged for severity based on serum creatinine or urine output [20].

CFB (mL) was defined as cumulative total fluid input minus cumulative total fluid output.

2.3. Data Collection

Demographic data, etiologies of ARDS, underlying comorbidities, Sequential Organ Failure Assessment (SOFA) score, and lung injury score were collected prior to ECMO initiation. The dates of hospital and ICU admission, mechanical ventilator initiation and liberation, ECMO cannulation and decannulation, RRT, ICU and hospital discharge, and time of death were recorded.

Fluid balance was calculated from total fluid intake (enteral fluids, intravenous fluids, blood products, and RRT replacement fluids) and output (urine output, enteral loss, drainage fluids, effluent dialysate from RRT, and insensible fluid loss), both of which were recorded daily throughout the ICU stay. Patients were stratified according to the quartiles of CFB during the first 3 days after ECMO support with the aim of elucidating the influence of early fluid balance during ECMO on clinical outcomes. Arterial blood gas parameters and mechanical ventilator settings were recorded at the time of ECMO initiation and at approximately 10 a.m. on days 1, 2, and 3 after ECMO initiation.

2.4. ECMO Systems

The ECMO circuit consisted of a centrifugal pump and hollow-fiber microporous membrane oxygenator with heparin-bound Carmeda BioActive Surface (Carmeda, a subsidiary of WL Gore and Associates, Flagstaff, AZ, USA) using Capiox emergent bypass system (Terumo, Tokyo, Japan). We used two wire-wound polyurethane vascular cannulas (DLP Medtronic, Minneapolis, MN, USA (inflow, 19F to 23F, and outflow, 17F to 21F)), and the femoral–jugular venovenous (VV) ECMO was established through percutaneous cannulation. Patients would be shifted to venoarterial (VA) mode ECMO if encountered with cardiopulmonary cerebral resuscitation, cardiac arrest, or pulmonary hypertension. ECMO mode was soon changed to VV ECMO once the hemodynamics of ARDS patients stabilized.

The ECMO gas flow rate was set high initially (10 L/min, pure oxygen), and the blood pump speed was gradually increased to achieve optimal oxygen saturation (90% or more). Modest volume replacement was necessary initially to improve unsteady ECMO blood flow and oxygenation. Red blood cell transfusion was performed to maintain hemoglobin at least above 10 g/dL. After optimizing the ECMO, it was crucial to remove the excessive extravascular lung water (i.e., no systemic edema, within 5% of dry weight) with diuretics or continuous renal replacement therapy to improve lung function and compliance. The hourly fluid balance goal was set at approximately −100 mL/h and modulated according to dry weight to achieve negative fluid balance, and extrapulmonary organ function was closely monitored.

2.5. Statistical Analysis

Continuous variables are presented as mean ± standard deviation or median (interquartile range), and categorical variables are reported as numbers (percentages). Analysis of variance, the Kruskal–Wallis test, a Student’s t-test, or the Mann–Whitney U test was used to compare continuous variables among groups. Categorical variables were tested using the chi-square test for equal proportions or Fisher’s exact test. Receiver op-
2.5. Statistical Analysis
Continuous variables are presented as mean ± standard deviation or median (interquartile range). Categorical variables are presented as frequency (percentage). All statistical analyses were performed using SPSS 22.0 statistical software, and a two-sided p value < 0.05 was considered statistically significant.

3. Results
3.1. Patients
During the study period, a total of 192 patients with severe respiratory failure receiving ECMO were included. After excluding 40 patients, 152 patients were in the final analysis, which focused on the impact of CFB during the first 3 days of ECMO on hospital mortality (Figure 1). Mortality rates were as follows: overall (53.3%), positive cumulative fluid balance (n = 98; 62.2%), and negative cumulative fluid balance (n = 54; 37%) (p < 0.001). The likelihood of hospital mortality was higher among patients in higher CFB quartiles. The ECMO techniques did not show significant difference, and a unified ECMO system was used during the study period. Patients in the later years (2012–2015) received significantly lower tidal volume, higher PEEP, lower peak inspiratory pressure, and lower mechanical power during the first 3 days of ECMO than did patients in the earlier years (2006–2011) (Table S1). However, hospital mortality was not significantly different between patients in the earlier years and later years of the study period (2006–2011: 77 patients, mortality rate 54.5%; 2012–2015: 75 patients, mortality rate 52%, p = 0.753).

Figure 1. Flowchart of enrolling patients with severe ARDS with ECMO support. ARDS, acute respiratory distress syndrome; ECMO, extracorporeal membrane oxygenation.

3.2. Comparison of Survivors and Nonsurvivors
As shown in Table 1, nonsurvivors tended to be older than survivors. We did not observe a significant difference between survivors and nonsurvivors in terms of fluid balance prior to ECMO; however, nonsurvivors presented a significantly higher CFB balance at 24 h and at 3 days after ECMO. Fluid balance was more positive after ECMO support from day 1 to day 7 in nonsurvivors than in survivors. Mean fluid balance...
in survivors changed to negative at day 3 after ECMO initiation, whereas mean fluid balance in nonsurvivors changed to negative at day 5 after ECMO initiation (Figure 2). Nonsurvivors received VA ECMO implantation more often than did survivors. In terms of ventilator settings during ECMO, nonsurvivors received significantly higher mechanical power, higher peak inspiratory pressure, and lower dynamic compliance than did survivors (all \( p < 0.05 \)). During ECMO, nonsurvivors required more inotropic support and more frequent RRT with higher SOFA scores (all \( p < 0.05 \)). The most common indications for RRT were fluid overload (n = 70, 80%), followed by refractory hyperkalemia (n = 8, 9%), uremia (n = 7, 8%), and severe metabolic acidosis (n = 3, 3%).

Table 1. Background characteristics and clinical variables: survivors and nonsurvivors.

| Variables | All (n = 152) | Survivors (n = 71) | Nonsurvivors (n = 81) | \( p \) |
|-----------|--------------|-------------------|----------------------|-------|
| Age (years) | 50.3 ± 16.4 | 46.0 ± 16.5 | 54.1 ± 15.4 | 0.002 |
| Male (gender) | 103 (67.8%) | 48 (67.6%) | 55 (67.9%) | 0.969 |
| Body mass index (kg/m\(^2\)) | 25.8 ± 5.3 | 26.0 ± 5.8 | 25.6 ± 4.7 | 0.631 |
| ARDS etiologies | | | | |
| Pulmonary cause | 118 (78%) | 59 (83%) | 59 (73%) | 0.130 |
| Extrapulmonary cause | 34 (22%) | 12 (17%) | 22 (27%) | 0.130 |
| Diabetes mellitus | 40 (26%) | 23 (32%) | 17 (21%) | 0.073 |
| Chronic liver disease | 40 (26%) | 11 (16%) | 29 (36%) | 0.005 |
| Chronic kidney disease | 17 (11.2%) | 8 (11.2%) | 9 (11.1%) | 0.976 |
| SOFA score before ECMO | 10.8 ± 3.2 | 10.3 ± 3.1 | 11.3 ± 3.2 | 0.067 |
| Lung injury score before ECMO | 3.4 ± 0.4 | 3.4 ± 0.4 | 3.3 ± 0.4 | 0.106 |
| \( \text{PaO}_2/\text{FiO}_2 \) (mmHg) before ECMO | 63 (52–88) | 64 (53–80) | 63 (52–107) | 0.168 |
| ECMO VA mode | 24 (15.8%) | 6 (8.5%) | 18 (22.2%) | 0.020 |
| ECMO blood flow rate (L/min) at day 1 | 3.4 ± 0.7 | 3.3 ± 0.8 | 3.5 ± 0.7 | 0.079 |
| ECMO blood flow rate (L/min) at day 3 | 3.8 ± 0.8 | 3.7 ± 1.0 | 3.9 ± 0.7 | 0.269 |
| SOFA score from day 1 to day 3 on ECMO | 9.6 ± 2.3 | 8.8 ± 1.9 | 10.4 ± 2.4 | <0.001 |
| \( \text{PaO}_2/\text{FiO}_2 \) (mmHg) from day 1 to day 3 on ECMO | 178 (131–240) | 200 (146–247) | 165 (124–211) | 0.588 |
| Ventilator settings from day 1 to day 3 on ECMO | | | | |
| Mechanical power (J/min) | 12.1 ± 6.2 | 10.9 ± 4.3 | 13.1 ± 7.4 | 0.022 |
| Tidal volume (mL/kg PBW) | 6.0 ± 2.2 | 6.1 ± 2.0 | 6.0 ± 2.4 | 0.914 |
| PEEP (cm H\(_2\)O) | 12.0 ± 3.3 | 12.3 ± 3.2 | 11.7 ± 3.3 | 0.202 |
| Peak inspiratory pressure (cm H\(_2\)O) | 31.7 ± 5.6 | 30.6 ± 5.1 | 32.8 ± 5.9 | 0.018 |
| Mean airway pressure (cm H\(_2\)O) | 17.7 ± 4.0 | 17.4 ± 3.6 | 17.9 ± 4.3 | 0.406 |
| Dynamic compliance (mL/cm H\(_2\)O) | 19.2 ± 8.1 | 21.1 ± 7.7 | 17.4 ± 8.1 | 0.006 |
| Fluid balance, mL | | | | |
| Before ECMO 24 h | 923 (– 258 to 2125) | 1027 (– 287 to 2341) | 795 (– 193 to 1781) | 0.751 |
| First 24 h | 1327 (57 to 2800) | 846 (−160 to 2095) | 1688 (219 to 3668) | 0.006 |
| Cumulative 3 days | 1190 (−873 to 3935) | 277 (−1798 to 2384) | 1927 (−100 to 5266) | <0.001 |
| Total fluid input, mL | | | | |
| Before ECMO 24 h | 3007 (2255–5926) | 4065 (3118–5441) | 5213 (4010–6010) | 0.083 |
| Cumulative 3 days | 13,013 (9996–17,095) | 12,675 (10,039–15,056) | 13,374 (9871–17,626) | 0.841 |
| Urine output, mL | | | | |
| Before ECMO 24 h | 1500 (550–2380) | 1585 (700–2750) | 1350 (475–2093) | 0.054 |
| Cumulative 3 days | 4890 (1375–8758) | 6653 (1731–9779) | 3760 (681–7530) | 0.042 |
| Blood product transfusions, mL | | | | |
| Red blood cell | 505 (390–1120) | 520 (395–1075) | 430 (385–1180) | 0.803 |
| Fresh frozen plasma | 560 (280–1120) | 490 (280–1100) | 590 (280–1120) | 0.800 |
| Platelet concentrate | 250 (130–560) | 230 (125–550) | 325 (198–573) | 0.721 |
| Hemoglobin (g/dL) | | | | |
| Before ECMO | 10.7 ± 2.4 | 11.5 ± 2.4 | 10.0 ± 2.3 | 0.008 |
| Day 1 | 10.7 ± 2.9 | 11.4 ± 3.4 | 9.9 ± 2.1 | 0.004 |
| Day 3 | 10.2 ± 1.6 | 10.2 ± 1.8 | 10.1 ± 1.3 | 0.881 |
| Serum creatinine (mg/dL) | | | | |
| Before ECMO | 2.0 ± 2.1 | 2.0 ± 2.4 | 2.0 ± 1.9 | 0.946 |
| Day 1 | 2.1 ± 1.8 | 2.1 ± 1.9 | 2.1 ± 1.8 | 0.782 |
| Day 3 | 2.0 ± 1.5 | 1.8 ± 1.7 | 2.1 ± 1.3 | 0.345 |
Table 1. Cont.

| Variables                      | All (n = 152) | Survivors (n = 71) | Nonsurvivors (n = 81) | p       |
|--------------------------------|---------------|--------------------|-----------------------|---------|
| AKI during ECMO (n)            |               |                    |                       |         |
| Stage 1                        | 62 (40.8%)    | 29 (40.8%)         | 33 (40.7%)            | 0.990   |
| Stage 2                        | 31 (20.4%)    | 10 (14.1%)         | 21 (25.9%)            | 0.071   |
| Stage 3                        | 20 (13.2%)    | 7 (9.9%)           | 13 (16%)              | 0.260   |
| Diuretics (n)                  | 106 (69.7%)   | 52 (73.2%)         | 54 (66.7%)            | 0.379   |
| Inotropes (n)                  | 133 (87.5%)   | 73 (76.6%)         | 80 (98.8%)            | <0.001  |
| RRT (n)                        | 88 (58%)      | 30 (42%)           | 58 (72%)              | <0.001  |
| RRT initiation prior to ECMO (n) | 15 (9.9%)    | 4 (5.6%)           | 11 (13.6%)            | 0.112   |
| Time from RRT to ECMO (days)   | 5 (2–18)      | 2 (1–2)            | 11 (5–20)             | 0.002   |
| RRT initiation during ECMO (n) | 73 (48%)      | 26 (36.7%)         | 47 (58%)              | 0.008   |
| Time from ECMO to RRT (days)   | 1 (0–3)       | 0 (0–1)            | 1 (0–5)               | 0.004   |
| Duration of ECMO (days)        | 9 (6–15)      | 9 (5–13)           | 11 (6–16)             | 0.089   |
| Duration of RRT (days)         | 13 (4–30)     | 16 (5–34)          | 11 (4–28)             | 0.163   |

Data are presented as mean ± standard deviation, count, or median (interquartile range). Abbreviations: AKI, acute kidney injury; ARDS, acute respiratory distress syndrome; ECMO, extracorporeal membrane oxygenation; FiO\textsubscript{2}, fraction of inspired oxygen; PaO\textsubscript{2}, partial pressure of oxygen in arterial blood; PBW, predicted body weight; PEEP, positive end-expiratory pressure; RRT, renal replacement therapy; SOFA, Sequential Organ Failure Assessment; VA, venoarterial.

Figure 2. Mean fluid balance in survivors and nonsurvivors of severe ARDS during the first week of ECMO support. Error bars represent the mean ± standard deviation. Dark line denotes survivors, and gray line denotes nonsurvivors. *p < 0.05 comparing survivors and nonsurvivors. ARDS, acute respiratory distress syndrome; ECMO, extracorporeal membrane oxygenation.

3.3. Comparisons of Cumulative Fluid Balance at 3 Days after ECMO

The value of CFB for each quartile was as follows: quartile 1 (<−873 mL), quartile 2 (−873 to 1190 mL), quartile 3 (1190 to 3935 mL), and quartile 4 (> 3935 mL). As shown in Table 2, there were no significant differences among the CFB quartiles in terms of age or body mass index. We observed no significant differences among the groups in terms of SOFA scores prior to ECMO initiation; however, SOFA scores during ECMO support were significantly higher in higher CFB quartiles (p = 0.041). We observed no significant differences among the groups in terms of oxygenation status (i.e., PaO\textsubscript{2}/FiO\textsubscript{2}) or ventilator settings during ECMO, except for lower dynamic compliance in CFB higher quartiles (p = 0.005). Urine outputs were lowest and the need for RRT were highest in the CFB quartile 4. The likelihood of hospital mortality was also higher among patients in higher CFB quartiles (p = 0.009).
Table 2. Background characteristics and clinical variables as a function of quartiles of cumulative fluid balance at 3 days after ECMO.

| Variables | First Quartile | Second Quartile | Third Quartile | Fourth Quartile | p  |
|-----------|----------------|-----------------|----------------|-----------------|----|
| Age (years) | 48.1 ± 16.9 | 51.0 ± 15.7 | 46.3 ± 16.0 | 55.3 ± 16.1 | 0.088 |
| Male (gender) | 27 (71.1%) | 28 (73.7%) | 27 (71.1%) | 21 (55.3%) | 0.347 |
| Body mass index (kg/m²) | 26.7 ± 6.6 | 26.4 ± 6.1 | 26.3 ± 5.3 | 23.8 ± 4.5 | 0.110 |
| SOFA score before ECMO | 9.9 ± 3.3 | 11.6 ± 2.7 | 10.9 ± 3.2 | 10.8 ± 3.3 | 0.153 |
| PaO₂/FiO₂ (mmHg) before ECMO | 58 (52–96) | 68 (56–87) | 57 (48–86) | 64 (54–95) | 0.998 |
| ECMO VA mode | 6 (15.8%) | 7 (18.4%) | 5 (13.2%) | 6 (15.8%) | 0.941 |
| ECMO blood flow rate (L/min) at day 1 | 3.4 ± 0.8 | 3.6 ± 0.6 | 3.3 ± 0.6 | 3.4 ± 0.8 | 0.570 |
| ECMO blood flow rate (L/min) at day 3 | 3.9 ± 0.8 | 4.1 ± 0.4 | 3.8 ± 1.1 | 3.7 ± 0.8 | 0.276 |
| SOFA score from day 1 to day 3 on ECMO | 9.0 ± 2.3 | 9.1 ± 2.0 | 9.6 ± 2.5 | 10.5 ± 2.2 | 0.041 |
| PaO₂/FiO₂ (mmHg) from day 1 to day 3 on ECMO | 167 (127–275) | 160 (127–241) | 192 (154–231) | 169 (130–222) | 0.696 |
| Ventilator settings from day 1 to day 3 on ECMO | | | | | |
| Mechanical power (J/min) | 12.3 ± 6.0 | 13.0 ± 6.2 | 11 ± 4.7 | 12.1 ± 7.9 | 0.589 |
| Tidal volume (mL/kg PBW) | 6.7 ± 2.6 | 6.0 ± 2.1 | 5.9 ± 1.7 | 5.5 ± 2.3 | 0.135 |
| PEEP (cm H₂O) | 11.9 ± 3.2 | 11.7 ± 3.5 | 12.4 ± 3.3 | 12 ± 3.1 | 0.839 |
| Peak inspiratory pressure (cm H₂O) | 30.5 ± 5.0 | 31.8 ± 5.7 | 31.8 ± 4.8 | 33.6 ± 6.2 | 0.101 |
| Mean airway pressure (cm H₂O) | 16.7 ± 3.8 | 17.5 ± 4.5 | 17.5 ± 3.4 | 19.0 ± 4.1 | 0.088 |
| Dynamic compliance (mL/cm H₂O) | 22.1 ± 7.8 | 19.6 ± 8.2 | 19.3 ± 7.5 | 15.6 ± 7.1 | 0.005 |
| Fluid balance, mL | | | | | |
| Before ECMO 24 h | 494 (−440 to 1537) | 363 (−324 to 1484) | 1102 (221 to 2244) | 1242 (−28 to 3118) | 0.024 |
| First 24 h | −376 (−1327 to 267) | 645 (57 to 2035) | 1539 (595 to 2427) | 3646 (2407 to 4379) | <0.001 |
| Cumulative 3 days | −2158 (−3844 to −1644) | 223 (−486 to 713) | 2179 (1797 to 2914) | 5995 (4556 to 8128) | <0.001 |
| Total fluid input, mL | | | | | |
| Before ECMO 24 h | 2760 (1856–3970) | 3700 (2745–4227) | 3025 (2230–4330) | 2980 (1870–4836) | 0.405 |
| First 24 h | 4065 (3158–5213) | 4047 (3350–5673) | 4696 (3545–5499) | 5795 (4800–7351) | 0.095 |
| Cumulative 3 days | 12,023 (9405–15,900) | 12,899 (9598–12,057) | 12,774 (10,088–16,847) | 14,654 (11,365–18,983) | 0.717 |
| Urine output, mL | | | | | |
| Before ECMO 24 h | 2300 (1008–3565) | 1215 (450–2343) | 1458 (753–2103) | 1050 (326–2038) | 0.001 |
| First 24 h | 2770 (1135–3695) | 1000 (300–2180) | 1690 (838–2466) | 635 (85–1360) | <0.001 |
| Cumulative 3 days | 8900 (6853–12,459) | 4492 (1439–9201) | 5285 (2788–7475) | 1417 (255–4530) | <0.001 |
| Blood product transfusions, mL | | | | | |
| Red blood cell | 450 (400–1243) | 420 (370–850) | 460 (384–1085) | 810 (500–1233) | 0.722 |
| Fresh frozen plasma | 890 (258–1268) | 695 (280–1003) | 525 (290–1120) | 475 (273–1105) | 0.998 |
| Platelet concentrate | 420 (115–565) | 400 (128–565) | 225 (128–485) | 240 (180–565) | 0.575 |
Table 2. Cont.

| Variables                        | First Quartile (n = 38) | Second Quartile (n = 38) | Third Quartile (n = 38) | Fourth Quartile (n = 38) | p  |
|----------------------------------|-------------------------|--------------------------|-------------------------|--------------------------|----|
| Hemoglobin (g/dL)                |                         |                          |                         |                          |    |
| Before ECMO                      | 11.0 ± 2.8              | 10.3 ± 1.8               | 10.7 ± 2.9              | 10.8 ± 2.1               | 0.870 |
| Day 1                            | 10.8 ± 3.2              | 10.5 ± 3.1               | 11.0 ± 3.3              | 10.3 ± 2.0               | 0.782 |
| Day 3                            | 10.6 ± 1.8              | 10.2 ± 1.6               | 10.3 ± 1.6              | 9.6 ± 1.3                | 0.118 |
| Serum creatinine (mg/dL)         |                         |                          |                         |                          |    |
| Before ECMO                      | 1.6 ± 1.6               | 2.3 ± 2.6                | 2.0 ± 2.1               | 2.1 ± 2.1                | 0.622 |
| Day 1                            | 1.8 ± 1.5               | 2.2 ± 1.7                | 2.0 ± 2.1               | 2.4 ± 2.0                | 0.595 |
| Day 3                            | 1.7 ± 1.4               | 2.2 ± 1.6                | 1.9 ± 1.5               | 2.1 ± 1.5                | 0.475 |
| AKI during ECMO (n)              |                         |                          |                         |                          |    |
| Stage 1                          | 14 (36.8%)              | 19 (50%)                 | 16 (42.1%)              | 13 (34.2%)               | 0.588 |
| Stage 2                          | 5 (13.2%)               | 3 (7.9%)                 | 10 (26.3%)              | 13 (34.2%)               | 0.015 |
| Stage 3                          | 4 (10.5%)               | 5 (13.2%)                | 4 (10.5%)               | 7 (18.4%)                | 0.697 |
| Diuretics (n)                    | 26 (68.4%)              | 28 (73.7%)               | 26 (68.4%)              | 26 (68.4%)               | 0.941 |
| Inotropes (n)                    | 32 (84.2%)              | 31 (81.6%)               | 34 (89.5%)              | 36 (94.7%)               | 0.130 |
| RRT (n)                          | 17 (44.7%)              | 23 (60.5%)               | 20 (52.6%)              | 28 (73.7%)               | 0.057 |
| RRT initiation prior to ECMO (n) | 2 (5.3%)                | 4 (10.5%)                | 4 (10.5%)               | 5 (13.2%)                | 0.272 |
| Time from RRT to ECMO (days)     | 11(2)                   | 3 (1-18)                 | 8 (2-14)                | 8 (4-25)                 | 0.831 |
| RRT initiation during ECMO (n)   | 15 (39.5%)              | 19 (50%)                 | 16 (42.1%)              | 23 (60.5%)               | 0.124 |
| Time from ECMO to RRT (days)     | 1 (0-10)                | 1 (0-9)                  | 1 (0-4)                 | 1 (0-2)                  | 0.147 |
| Duration of RRT (days)           | 13 (4-32)               | 15 (7-36)                | 12 (6-26)               | 11 (4-24)                | 0.549 |
| Hospital mortality, n (%)        | 14 (36.8%)              | 18 (47.4%)               | 21 (55.3%)              | 28 (73.7%)               | 0.009 |

Data are presented as mean ± standard deviation, count, or median (interquartile range). Abbreviations: AKI, acute kidney injury; ECMO, extracorporeal membrane oxygenation; FiO₂, fraction of inspired oxygen; PaO₂, partial pressure of oxygen in arterial blood; PBW, predicted body weight; PEEP, positive end-expiratory pressure; RRT, renal replacement therapy; SOFA, Sequential Organ Failure Assessment; VA, venoarterial.
3.4. Outcomes

As shown in Table 3, there was a stepwise increase in hospital mortality corresponding to an increase in CFB quartile, with significant between-group differences in terms of 28-, 60-, and 90-day hospital mortality (all \( p < 0.05 \)). We observed no significant differences among the quartiles in terms of ECMO duration, mechanical ventilator duration, length of ICU stay, or length of hospital stay. Patients in lower CFB quartiles presented more ECMO-free days by day 28; however, the effect was not significant. We observed significantly higher 28- and 60-day ventilator-free days in lower CFB quartiles (\( p = 0.002 \) and 0.001, respectively). We also observed significantly lower overall 90-day survival rates in quartile 4 (overall comparison, \( p = 0.001 \), log-rank test), as follows: quartile 1 (63.2%), quartile 2 (55.3%), quartile 3 (50%), and quartile 4 (31.6%). We observed no significant differences in overall 90-day survival rates among quartiles 1, 2, or 3 (Figure 3).

Figure 3. Kaplan–Meier 90-day survival curves of patients undergoing ECMO for severe acute respiratory distress syndrome, as stratified by quartiles of cumulative fluid balance during the first 3 days of ECMO. ECMO, extracorporeal membrane oxygenation.

3.5. Factors Associated with Hospital Mortality

After adjusting for significant confounding variables, Cox proportional hazard regression models revealed that CFB during the first 3 days of ECMO was independently associated with an increased risk of death (adjusted HR 1.110 [95% CI 1.027–1.201]; \( p = 0.009 \)) when CFB was considered as a continuous variable. When the quartiles of CFB were considered as categorical variables with the first quartile as the reference category, the risk of death revealed a stepwise increasing trend with an increase in CFB quartile. The risk of death in quartile 4 was significantly higher than in quartile 1 (adjusted HR 2.710 [95%
1.325]; \( p = 0.004 \); however, differences among quartiles 1, 2, and 3 did not reach the level of significance (Table 4).

### Table 3. Clinical outcomes as a function of cumulative fluid balance at 3 days after ECMO.

| Variables                        | First Quartile (n = 38) | Second Quartile (n = 38) | Third Quartile (n = 38) | Fourth Quartile (n = 38) | \( p \) |
|----------------------------------|-------------------------|--------------------------|-------------------------|--------------------------|-------|
| Mortality                        |                         |                          |                         |                          |       |
| 28-day hospital mortality, n (%) | 9 (23.7%)               | 11 (28.9%)               | 16 (42.1%)              | 24 (63.2%)               | <0.001|
| 60-day hospital mortality, n (%) | 13 (34.2%)              | 17 (44.7%)               | 18 (47.4%)              | 25 (65.8%)               | 0.002 |
| 90-day hospital mortality, n (%) | 14 (36.8%)              | 17 (44.7%)               | 19 (50%)                | 26 (68.4%)               | 0.001 |
| Other outcomes                   |                         |                          |                         |                          |       |
| Duration of ECMO (days)          | 8 (5–16)                | 12 (7–18)                | 10 (7–15)               | 7 (4–12)                 | 0.209 |
| Duration of mechanical ventilator (days) | 25 (11–31)            | 27 (14–44)               | 22 (15–40)              | 18 (10–36)               | 0.380 |
| Length of ICU stay (days)        | 27 (13–38)              | 29 (16–49)               | 27 (18–48)              | 18 (10–39)               | 0.451 |
| Length of hospital stay (days)   | 41 (27–61)              | 49 (23–73)               | 40 (22–69)              | 28 (11–53)               | 0.334 |
| ECMO-free days at day 28         | 15 (0–22)               | 9 (0–19)                 | 8 (0–19)                | 0 (0–14)                 | 0.082 |
| Ventilator-free days at day 28   | 0 (0–16)                | 0 (0–5)                  | 0 (0–4)                 | 0 (0–0)                  | 0.002 |
| Ventilator-free days at day 60   | 32 (0–48)               | 14 (0–37)                | 0 (0–36)                | 0 (0–0)                  | 0.001 |

Data are presented as mean ± standard deviation, count, or median (interquartile range). Abbreviations: ECMO, extracorporeal membrane oxygenation; ICU, intensive care unit.

### Table 4. Cox proportional hazard regression models with 90-day hospital mortality as outcome.

| Variables                                           | Adjust HR (95% CI) | \( p \) |
|------------------------------------------------------|--------------------|-------|
| Model 1                                              |                    |       |
| Cumulative fluid balance from day 1 to 3 on ECMO (per 1-L increase) | 1.110 (1.027–1.201) | 0.009 |
| Model 2                                              |                    |       |
| Cumulative fluid balance from day 1 to 3 on ECMO      |                    |       |
| First quartile                                       | 1.00 (reference)   |       |
| Second quartile                                      | 1.200 (0.569–2.531)| 0.632 |
| Third quartile                                       | 1.675 (0.819–3.425)| 0.158 |
| Fourth quartile                                      | 2.710 (1.379–5.325)| 0.004 |

Abbreviations: CI, confidence interval; ECMO, extracorporeal membrane oxygenation; FiO\(_2\), fraction of inspired oxygen; HR, hazard ratio; PaO\(_2\), partial pressure of oxygen in arterial blood. The multivariate analysis models included age, pulmonary or extrapulmonary cause of acute respiratory distress syndrome, diabetes mellitus, chronic liver disease, immunocompromised status, ECMO venaarterial mode use, mean Sequential Organ Failure Assessment score from day 1 to 3 on ECMO, mean values of ventilatory variables from day 1 to 3 on ECMO (PaO\(_2\)/FiO\(_2\), positive end-expiratory pressure, peak inspiratory pressure, dynamic compliance, and mechanical power), inotropes, renal replacement therapy, cumulative total fluid input, and cumulative urine output from day 1 to 3 on ECMO. Model 1: added cumulative fluid balance from day 1 to 3 on ECMO as a continuous variable. Model 2: added cumulative fluid balance from day 1 to 3 on ECMO as categorical variables with the first quartile as the reference category.

### 3.6. Comparisons of VV-ECMO- and VA-ECMO-Supported ARDS Patients

As shown in Table 5, VA ECMO patients had a lower percentage of diabetes mellitus. The SOFA score was significantly higher in VA ECMO patients before ECMO. In terms of ventilator settings during ECMO, VA ECMO cases received significantly higher mechanical power, higher tidal volume, lower PEEP, and higher peak inspiratory pressure than did VV ECMO cases (all \( p < 0.05 \)). We did not observe a significant difference between VV ECMO and VA ECMO cases in terms of fluid balance before and during ECMO. No significant differences were observed between the two groups in terms of SOFA score, acute kidney injury development, diuretic use, inotropic support, and RRT use during ECMO. VA ECMO patients were associated with significantly higher hospital mortality than VV ECMO patients (\( p = 0.020 \)).
| Variables                                      | VV ECMO (n = 128) | VA ECMO (n = 24) | p    |
|-----------------------------------------------|-------------------|------------------|------|
| Age (years)                                   | 51.2 ± 16.4       | 45.9 ± 15.2      | 0.147|
| Male (gender)                                 | 89 (69.5%)        | 14 (58.3%)       | 0.281|
| Body mass index (kg/m²)                       | 25.8 ± 5.4        | 25.4 ± 4.3       | 0.794|
| ARDS etiologies                               |                   |                  |      |
| Pulmonary cause                               | 103 (80.5%)       | 15 (62.5%)       | 0.053|
| Extrapulmonary cause                          | 25 (19.5%)        | 9 (37.5%)        | 0.053|
| Diabetes mellitus                             | 38 (29.7%)        | 2 (8.3%)         | 0.041|
| Chronic liver disease                         | 19 (14.8%)        | 2 (8.3%)         | 0.531|
| Immunocompromised status                      | 33 (25.8%)        | 7 (29.2%)        | 0.730|
| Chronic kidney disease                        | 16 (12.5%)        | 1 (4.2%)         | 0.313|
| SOFA score before ECMO                        | 10.6 ± 3.1        | 12.2 ± 3.0       | 0.023|
| Lung injury score before ECMO                 | 3.4 ± 0.4         | 3.3 ± 0.5        | 0.384|
| PaO₂/FiO₂ (mmHg) before ECMO                 | 63 (53–93)        | 63 (49–85)       | 0.787|
| ECMO blood flow rate (L/min) at day 1         | 3.4 ± 0.7         | 3.4 ± 0.6        | 0.942|
| ECMO blood flow rate (L/min) at day 3         | 3.9 ± 0.8         | 3.8 ± 0.8        | 0.710|
| SOFA score from day 1 to day 3 on ECMO        | 9.6 ± 2.2         | 9.5 ± 3.0        | 0.862|
| PaO₂/FiO₂ (mmHg) from day 1 to day 3 on ECMO  | 180 (135–221)     | 160 (106–442)    | 0.078|
| Ventilator settings from day 1 to day 3 on ECMO|                   |                  |      |
| Mechanical power (J/min)                      | 11.5 ± 6.0        | 15.0 ± 6.7       | 0.011|
| Tidal volume (mL/kg PBW)                      | 5.8 ± 2.0         | 7.1 ± 2.7        | 0.014|
| Peak inspiratory pressure (cm H₂O)            | 12.3 ± 3.3        | 10.4 ± 2.6       | 0.007|
| Mean airway pressure (cm H₂O)                 | 17.8 ± 3.9        | 17.3 ± 4.4       | 0.592|
| Dynamic compliance (mL/cm H₂O)                | 19.2 ± 7.9        | 18.9 ± 9.1       | 0.870|
| Fluid balance, mL                             |                   |                  |      |
| Before ECMO 24 h                              | 932 (−148 to 2125) | 904 (−271 to 196) | 0.919|
| First 24 h                                    | 1410 (53 to 2800) | 1084 (78 to 2831) | 0.960|
| Cumulative 3 days                             | 1301 (−873 to 3935) | 833 (−894 to 4012) | 0.953|
| Total fluid input, mL                         |                   |                  |      |
| Before ECMO 24 h                              | 2938 (2243–3930)  | 4150 (3665–6359) | 0.587|
| First 24 h                                    | 4464 (3513–5828)  | 5005 (4398–6241) | 0.325|
| Cumulative 3 days                             | 12,899 (9774–16,926) | 13,425 (11,044–18,103) | 0.388|
| Urine output, mL                              |                   |                  |      |
| Before ECMO 24 h                              | 1365 (530–2350)   | 1857 (975–2721)  | 0.408|
| First 24 h                                    | 1460 (396–2705)   | 826 (168–2264)   | 0.316|
| Cumulative 3 days                             | 5385 (1490–8870)  | 3750 (1040–7368) | 0.362|
| Blood product transfusions, mL                |                   |                  |      |
| Red blood cell                                | 520 (393–1098)    | 420 (385–1306)   | 0.634|
| Fresh frozen plasma                           | 560 (265–1110)    | 490 (228–1120)   | 0.689|
| Platelet concentrate                          | 325 (190–560)     | 235 (113–543)    | 0.247|
| Hemoglobin (g/dL)                             |                   |                  |      |
| Before ECMO                                   | 10.7 ± 2.4        | 10.7 ± 2.4       | 0.930|
| Day 1                                         | 10.6 ± 2.9        | 11.0 ± 3.0       | 0.632|
| Day 3                                         | 10.1 ± 1.6        | 10.3 ± 1.4       | 0.700|
| Serum creatinine (mg/dL)                      |                   |                  |      |
| Before ECMO                                   | 2.0 ± 2.2         | 1.9 ± 1.5        | 0.715|
| Day 1                                         | 2.1 ± 1.9         | 2.0 ± 1.0        | 0.662|
| Day 3                                         | 2.0 ± 1.6         | 1.9 ± 1.0        | 0.928|
| AKI during ECMO (n)                           |                   |                  |      |
| Stage 1                                       | 51 (39.8%)        | 11 (45.8%)       | 0.584|
| Stage 2                                       | 27 (21.1%)        | 4 (16.7%)        | 0.785|
| Stage 3                                       | 15 (11.7%)        | 5 (20.8%)        | 0.225|
| Diuretics (n)                                 | 91 (71.1%)        | 15 (62.5%)       | 0.400|
| Inotropes (n)                                 | 110 (85.9%)       | 23 (95.8%)       | 0.311|
| RRT (n)                                       | 74 (57.8%)        | 14 (58.3%)       | 0.962|
| RRT initiation prior to ECMO (n)              | 13 (10.2%)        | 2 (8.3%)         | 1.000|
| Time from RRT to ECMO (days)                  | 5 (2–19)          | 8 (4)            | 0.720|
| RRT initiation during ECMO (n)                | 61 (47.7%)        | 12 (50%)         | 0.833|
| Time from ECMO to RRT (days)                  | 1 (0–4)           | 0 (0–1)          | <0.001|
| Duration of ECMO (days)                       | 10 (6–16)         | 8 (4–11)         | 0.248|
| Duration of RRT (days)                        | 13 (4–29)         | 10 (4–34)        | 0.737|
| Hospital mortality, n (%)                     | 63 (49.2%)        | 18 (75%)         | 0.020|

Data are presented as mean ± standard deviation, count or median (interquartile range). Abbreviations: AKI, acute kidney injury; ARDS, acute respiratory distress syndrome; ECMO, extracorporeal membrane oxygenation; FiO₂, fraction of inspired oxygen; PaO₂, partial pressure of oxygen in arterial blood; PBW, predicted body weight; PEEP, positive end-expiratory pressure; RRT, renal replacement therapy; SOFA, Sequential Organ Failure Assessment; VA, venoarterial; VV, venovenous.
4. Discussion

The primary insight gained in this research was the fact that excessive CFB during the first 3 days of ECMO was independently associated with an increased risk of death in severe ARDS patients. We also observed higher mortality rates in higher CFB quartiles.

Most severe ARDS patients receive VV ECMO for respiratory support, and there is no direct hemodynamic support provided by the extracorporeal circuit. However, unstable hemodynamics is frequently encountered during the early phase of ECMO, and it is necessary to add volume for ECMO enforcement. Hemodynamics are managed with fluid or blood volume replacement and inotropes in the same fashion as in patients without VV ECMO support [1]. Bleeding remains a clinically significant ECMO complication by anticoagulation, and blood transfusions are needed to correct anemia or coagulopathy.

The blood volume during ECMO should be maintained at a level high enough to keep right atrial pressure in the range of 5–10 mmHg. This will assure adequate volume for venous drainage, as long as the resistance of the drainage cannula is appropriate. Echocardiography is an excellent tool to assess hemodynamic function and help guide management during VV ECMO. If cardiac failure occurs during VV ECMO support, the patients could be converted to VA ECMO. If the systemic perfusion pressure is inadequate (i.e., low urine output or poor perfusion), pressure can be increased by adding blood volume through transfusion or by using low doses of vasopressors. If systemic oxygen delivery is not adequate (i.e., venous saturation less than 70%), the pump flow should be increased until perfusion is adequate. If blood volume is required to gain adequate flow, the relative advantages of using blood products and crystalloid solutions should be considered [7].

Researchers have yet to establish optimal fluid balance targets beyond the initial resuscitation period for patients treated with ECMO (including severe ARDS patients). In guidelines published by the Extracorporeal Life Support Organization, the goal of fluid management in patients with ECMO should be to maintain normal extracellular fluid volume (i.e., dry weight), adequate hematocrit to optimize oxygen delivery, normal body weight without fluid overload, and normal blood volume [7]. However, acute inflammatory reactions during the early phase of ECMO support can increase capillary leakage with increased vascular permeability and tissue edema and may lead to eventual organ injury [21]. Furthermore, this situation can be exacerbated by excessive crystalloid infusion, which increases the likelihood of fluid overload. This means that practitioners should implement a conservative fluid management strategy aimed at achieving negative fluid balance via aggressive diuresis and continuous hemofiltration when necessary [1,7].

During the early phase of ECMO, fluid overload can profoundly affect outcomes. One previous report concluded that early positive fluid balance (particularly at day 3 of VV or VA ECMO) is an independent predictor of 90-day mortality among adult patients [16]. Another retrospective study found that excessive CFB during the first 3 days of ECMO increased the risk of mortality, regardless of whether the patients were suffering from cardiovascular or pulmonary diseases and whether VV or VA ECMO was used [17]. Note, however, that those studies included all patients requiring ECMO for circulatory or pulmonary failure, including patients with severe ARDS (i.e., n = 53 and 75, respectively). In other words, those studies did not evaluate the effect of early fluid status during ECMO on clinical outcomes exclusively among severe ARDS patients. Furthermore, neither study investigated the correlation between early fluid status during ECMO and clinical or ventilatory variables in severe ARDS patients. In the current study, focusing exclusively on severe ARDS patients receiving ECMO (n = 152), fluid status was not significantly different between VV and VA ECMO patients before and during ECMO. However, CFB during the first 3 days of ECMO was independently associated with hospital mortality. We also observed a stepwise increase in hospital mortality corresponding to higher CFB quartiles.

Fluid overload brings with it an elevated risk of pulmonary edema, which can have profound effects on oxygenation and lung compliance with a corresponding increase in respiratory work and difficulties pertaining to ventilator weaning [13,14,22,23]. We did
not observe a significant difference between CFB quartiles in terms of oxygenation status (i.e., PaO\textsubscript{2}/FiO\textsubscript{2}) during ECMO. Lung compliance is a prerequisite for weaning from ECMO [1,3,4]; however, we observed significantly lower dynamic compliance in higher CFB quartiles (i.e., lowest in CFB quartile 4). We also observed that patients in higher CFB quartiles had fewer ECMO-free days at day 28, though the effect was not significant. Taken together, these results indicate that fluid overload could influence lung compliance, delay weaning, and increase ECMO duration [7,24]. The number of ventilator-free days at day 28 and day 60 was significantly lower in higher CFB quartiles, indicating that early fluid status during ECMO may also affect the weaning of severe ARDS patients from mechanical ventilators. Finally, mechanical ventilator settings were associated with mortality in ARDS patients undergoing ECMO [2–4], and VA ECMO patients received higher airway pressures and higher tidal volume during ECMO than VV ECMO patients, which may be associated with significantly higher hospital mortality in VA ECMO patients.

Critically ill patients undergoing ECMO face a higher risk of developing acute kidney injury, which may predispose them to fluid overload and impaired oxygen transport, thereby necessitating RRT and increasing the risk of death [2,16,24–26]. The factors contributing to acute kidney injury during ECMO included premorbid comorbidities and acute inflammatory and immune-mediated processes, related to the exposure of blood to the extracorporeal circulation, hemodynamic instability, hypercoagulable state, hemolysis, and exposure to nephrotoxic substances [24,25]. One recent international multicenter cohort reported that the need for RRT in severe ARDS patients receiving ECMO was independently associated with 6-month mortality [26]. In our cohort, the strongest indication for RRT during ECMO was fluid overload (70 patients; 80%). Furthermore, RRT itself was a strong indicator of mortality, as indicated by the fact that the incidence of fluid accumulation requiring RRT was higher among nonsurvivors than among survivors. Note also that the highest likelihood of requiring RRT and the highest mortality were both observed in CFB quartile 4. In terms of renal function (i.e., serum creatinine), we did not observe significant differences between survivors and nonsurvivors before and during ECMO or among patients in different CFB quartiles during ECMO. Nonetheless, the initiation of RRT may be an indicator of multiple organ failure, which is no doubt associated with poor outcomes [8,24].

The most common cause of death among ARDS patients is multiorgan failure [22]. One international multicenter study reported that for severe ARDS patients, extrapulmonary organ failure during ECMO had a significantly negative impact on 6-month mortality [26]. Our findings revealed no significant differences between survivors and nonsurvivors in terms of fluid balance or SOFA score prior to ECMO initiation; however, fluid balance and SOFA scores during the first 3 days of ECMO were significantly higher among nonsurvivors than among survivors. We also observed higher SOFA scores during ECMO in patients with higher CFB quartiles, which may reflect higher severity in illness and organ dysfunction. Excess fluid accumulation has been shown to exacerbate tissue edema, stretch vascular walls, worsen vascular permeability, and eventually promote organ dysfunction with corresponding effects on clinical outcomes [8,11,12,23,27]. Nonetheless, determining the causal relationship between fluid overload and organ dysfunction was difficult due to the retrospective nature of our study.

This study was hindered by a number of limitations. First, our focus on patients receiving ECMO for severe ARDS limited the number of patients in the CFB quartiles. Furthermore, this was a retrospective study conducted in a single tertiary-care referral facility. These facts no doubt limit the generalizability of our findings. Second, we made no attempt to assess the type or amount of fluid administration (e.g., colloids, crystalloids, or blood products), inotrope dosage, diuretic dosage, and RRT modalities’ dose and frequency. Furthermore, we did not analyze hemodynamic parameters as an indicator of fluid status. Third, we did not analyze fluid output other than urine. Thus, we were unable to determine the effects of limiting excess fluid intake or promoting fluid output within the context of clinical outcomes. Note, however, that the definition of fluid overload has yet to be
clearly established, and researchers have yet to determine the optimal time point at which CFB should be assessed to predict outcomes. Finally, our objective in this observational study was to evaluate the correlation between CFB and mortality during the early phase of ECMO, without considering issues pertaining to causality.

5. Conclusions

Our findings revealed that CFB during the first 3 days of ECMO was independently associated with 90-day hospital mortality, as indicated by higher mortality rates corresponding to higher CFB quartiles. These results indicate the need for a conservative fluid strategy to prevent fluid overload during the early phase of ECMO when dealing with severe ARDS patients.

Supplementary Materials: The following are available online at https://www.mdpi.com/article/10.3390/membranes11080567/s1. Table S1: Ventilator settings before and during the first 3 days of ECMO between the earlier years and later years.

Author Contributions: Conceptualization, L.-C.C., L.-P.C., S.-W.L. (Shih-Wei Lin) and S.-W.L. (Shaw-Woei Leu); methodology, L.-C.C., Y.-C.C. (Yu-Ching Chiou), H.-H.L., Y.-C.C. (Yung-Chang Chen), Y.-J.L. and C.-J.C.; software, L.-C.C., Y.-J.L. and C.-J.C.; validation, L.-C.C., L.-P.C. and H.-H.L.; formal analysis, L.-C.C., Y.-C.C. (Yung-Chang Chen), Y.-J.L., C.-J.C. and H.-H.L.; investigation, L.-C.C., L.-P.C. and S.-W.L. (Shih-Wei Lin); resources, L.-C.C., H.-H.L. and C.-J.C.; data curation, L.-C.C., L.-P.C. and S.-W.L. (Shih-Wei Lin); writing—original draft preparation, L.-C.C., Y.-C.C. (Yu-Ching Chiou) and H.-H.L.; writing—review and editing, L.-C.C. and S.-W.L. (Shaw-Woei Leu); visualization, K.-W.C., H.-C.H., C.-C.H. and K.-C.K.; supervision, C.-C.H. and K.-C.K.; project administration, L.-C.C.; funding acquisition, L.-C.C. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by grant CMRPG3K1151 from Chang Gung Memorial Hospital.

Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Institutional Review Board of CGMH IRB No. 20160632B0.

Informed Consent Statement: Patient consent was waived due to the retrospective and observational nature of the study.

Data Availability Statement: All data will be available from the corresponding author on reasonable request.

Acknowledgments: The authors would like to express their appreciation for the patients and staff in the ICUs at Chang Gung Memorial Hospital.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Brodie, D.; Bacchetta, M. Extracorporeal membrane oxygenation for ARDS in adults. N. Engl. J. Med. 2011, 365, 1905–1914. [CrossRef] [PubMed]
2. Giani, M.; Redaelli, S.; Siragusa, A.; Fumagalli, B.; Rona, R.; Foti, G. Extracorporeal Gas Exchange for Acute Respiratory Distress Syndrome: Open Questions, Controversies and Future Directions. Membranes 2021, 11, 172. [CrossRef]
3. Abrams, D.; Brodie, D. Extracorporeal Membrane Oxygenation for Adult Respiratory Failure: 2017 Update. Chest 2017, 152, 639–649. [CrossRef] [PubMed]
4. Combes, A.; Pesenti, A.; Ranieri, V.M. Fifty Years of Research in ARDS. Is Extracorporeal Circulation the Future of Acute Respiratory Distress Syndrome Management? Am. J. Respir. Crit. Care Med. 2017, 195, 1161–1170. [CrossRef] [PubMed]
5.Gattinoni, L.; Vassalli, F.; Romitti, F.; Vasques, F.; Pasticci, I.; Duscio, E.; Quintel, M. Extracorporeal gas exchange: When to start and how to end? Crit. Care 2019, 23 (Suppl. S1), 203. [CrossRef]
6. Ficial, B.; Vasques, F.; Zhang, J.; Whebell, S.; Slattery, M.; Lamas, T.; Daly, K.; Agnew, N.; Camporota, L. Physiological Basis of Extracorporeal Membrane Oxygenation and Extracorporeal Carbon Dioxide Removal in Respiratory Failure. Membranes 2021, 11, 225. [CrossRef]
7. Extracorporeal Life Support Organization. Available online: https://www.elso.org/Resources/Guidelines.aspx (accessed on 6 June 2021).
